1. One-year follow-up on liraglutide treatment for prediabetes and overweight/obesity in clozapine- or olanzapine-treated patients.
- Author
-
Svensson CK, Larsen JR, Vedtofte L, Jakobsen MSL, Jespersen HR, Jakobsen MI, Koyuncu K, Schjerning O, Nielsen J, Ekstrøm CT, Correll CU, Vilsbøll T, and Fink-Jensen A
- Subjects
- Adolescent, Adult, Aged, Antipsychotic Agents adverse effects, Antipsychotic Agents therapeutic use, Blood Glucose drug effects, Body Weight drug effects, C-Peptide drug effects, Clozapine adverse effects, Clozapine therapeutic use, Denmark epidemiology, Fasting, Female, Follow-Up Studies, Glucagon-Like Peptide-1 Receptor agonists, Glycated Hemoglobin drug effects, Humans, Hypoglycemic Agents administration & dosage, Hypoglycemic Agents therapeutic use, Lipid Metabolism drug effects, Liraglutide administration & dosage, Liraglutide therapeutic use, Male, Middle Aged, Obesity chemically induced, Obesity epidemiology, Olanzapine adverse effects, Olanzapine therapeutic use, Overweight chemically induced, Overweight epidemiology, Placebos administration & dosage, Prediabetic State chemically induced, Prediabetic State epidemiology, Schizophrenia blood, Schizophrenia diagnosis, Schizophrenia drug therapy, Young Adult, Hypoglycemic Agents pharmacology, Liraglutide pharmacology, Obesity drug therapy, Overweight drug therapy, Prediabetic State drug therapy
- Abstract
Objective: Treatment with most antipsychotics is associated with an increased risk of weight gain and metabolic disturbances. In a randomized trial, we previously demonstrated that 16 weeks of glucagon-like peptide-1 receptor agonist liraglutide treatment vs. placebo significantly reduced glucometabolic disturbances and body weight in prediabetic, overweight/obese schizophrenia-spectrum disorder patients treated with clozapine or olanzapine. The aim of this study was to investigate whether the beneficial effects of the 16-week intervention were sustained beyond the intervention period., Method: One year after completion of the intervention, we investigated changes in body weight, fasting glucose, glycated hemoglobin, C-peptide, and lipids comparing 1-year follow-up levels to end of treatment (week 16) and baseline (week 0) levels., Results: From end of treatment to the 1-year follow-up, body weight had increased in the liraglutide-treated group. However, compared to baseline levels, the placebo-subtracted body weight loss remained significantly reduced (-3.8 kg, 95% CI: -7.3 to -0.2, P = 0.04). Fasting glucose, glycated hemoglobin, C-peptide, and lipids had each returned to baseline levels 1 year after stopping liraglutide., Conclusion: The body weight reduction during 16 weeks of liraglutide treatment was partially sustained 1 year after the intervention was completed. However, the improvements in other metabolic parameters returned to baseline levels., (© 2018 John Wiley & Sons A/S. Published by John Wiley & Sons Ltd.)
- Published
- 2019
- Full Text
- View/download PDF